AEON Biopharma SEC filings document its ABP-450 biosimilar program, operating and financial results, governance matters, capital structure, and NYSE American listing-status disclosures. Form 8-K reports cover material events such as financial results, Regulation FD presentations, executive appointments and compensatory arrangements, and continued-listing rule notices tied to stockholders’ equity requirements.
Proxy statements record shareholder voting procedures and meeting proposals, including capital-structure approvals tied to Class A common stock, warrants, and senior secured convertible note matters. The filings also identify AEON’s Class A common stock listed on NYSE American and describe disclosure topics common to a development-stage biopharmaceutical issuer.
FISCHER JOST reported acquisition or exercise transactions in this Form 4 filing.
AEON Biopharma director Jost Fischer received an equity grant in the form of restricted stock units. The award covers 222,684 RSUs granted on June 17, 2026 at no cash cost, increasing his direct holdings to 489,469 shares of Class A Common Stock.
The RSUs vest in full on the earlier of the one-year anniversary of the grant date or the date of AEON Biopharma’s 2027 annual meeting of stockholders, conditioned on his continued service through the applicable vesting date. This is a compensation-related grant rather than an open‑market share purchase.
Carter Eric G reported acquisition or exercise transactions in this Form 4 filing.
AEON Biopharma director Eric G. Carter received an equity grant of 222,684 restricted stock units (RSUs) of Class A Common Stock. The award was granted on June 17, 2026 and carries no purchase price. The RSUs vest in full on the earlier of one year after the grant date or the 2027 annual stockholder meeting, subject to his continued service. Following this grant, Carter holds 258,705 shares directly.
AEON Biopharma, Inc. reported results from its Annual Meeting of Stockholders held on June 17, 2026. Stockholders elected Marc Forth and Seongsoo Park as Class III directors to terms ending at the 2029 annual meeting, with 13,297,322 and 13,117,299 votes "for," respectively.
Stockholders also ratified the appointment of KPMG LLP as AEON Biopharma’s independent registered public accounting firm for the fiscal year ended December 31, 2026, with 21,502,418 votes "for," 18,217 "against" and 1,498 "abstain."
AEON Biopharma, Inc. furnished a new corporate investor presentation on its website and via an exhibit to a current report. The presentation, dated May 2026 and labeled as Exhibit 99.1, may be used by management in future meetings to discuss the company.
The company states that the presentation includes a slide titled “Forward-Looking Statements” for important cautionary information. AEON also clarifies that the materials furnished under Item 7.01, including Exhibit 99.1, are not deemed filed under the securities laws and are not automatically incorporated into other SEC filings.
AEON Biopharma, Inc. reported a net loss of $11.8 million for the three months ended March 31 2026, compared with net income of $9.1 million a year earlier. Operating expenses rose as selling, general and administrative costs reached $3.9 million and research and development expenses were $2.0 million.
Results were heavily influenced by fair value movements on financing instruments, including an $8.7 million loss on convertible notes and a $4.7 million gain on warrants. AEON ended the quarter with cash and cash equivalents of $6.2 million and total liabilities of $25.4 million, resulting in a stockholders’ deficit of $16.8 million.
The company raised equity through its at-the-market program, issuing 1,278,776 shares for net proceeds of about $1.7 million, and completed a $6.0 million PIPE financing spanning late 2025 and early 2026. It also exchanged $15.0 million of Daewoong-held convertible notes into equity, a new $1.5 million note and 8.0 million warrants at $1.09392/share.
Management disclosed recurring losses, a significant accumulated deficit of $482.6 million, limited cash and dependence on additional financing, concluding there is substantial doubt about AEON’s ability to continue as a going concern. The company continues developing its ABP‑450 botulinum toxin biosimilar program and plans to advance analytical and regulatory interactions with the FDA during 2026.
AEON Biopharma reported first-quarter 2026 results and a corporate update focused on its ABP-450 biosimilar program and balance sheet. The company recorded a net loss of $11.8 million for the quarter, compared with net income of $9.1 million in the prior-year period, largely driven by fair value changes in financial instruments.
Operating expenses rose as selling, general and administrative costs reached $3.9 million and research and development spending was $2.0 million. AEON ended March 31, 2026 with cash and cash equivalents of $6.2 million, and stated that, including $0.9 million of April ATM proceeds, this is expected to fund operations into the third quarter of 2026.
The company highlighted positive FDA feedback from a BPD Type 2a meeting supporting ABP-450’s analytical similarity strategy under the 351(k) biosimilar pathway. AEON also completed a $6 million PIPE financing and a Daewoong note exchange, which together reduced outstanding debt by more than 90% and contributed to shrinking total stockholders’ deficit from $(55.0) million to $(16.8) million.
AEON Biopharma, Inc. is asking stockholders to vote at its 2026 Annual Meeting on June 17, 2026 at 10:00 a.m. Pacific Time at its Irvine, California offices. Holders of Class A Common Stock at the close of business on April 21, 2026, when 26,307,211 shares were outstanding, may vote in person or by proxy.
Stockholders are being asked to elect Class III directors Marc Forth and Seongsoo Park to terms running to the 2029 annual meeting, and to ratify KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026. The proxy statement also details board structure, committee assignments, governance policies, and 2025 compensation for key executives, including new CEO Robert Bancroft, Chief Medical Officer Chad Oh, and Chief Legal Officer Alex Wilson.
Bencich John reported acquisition or exercise transactions in this Form 4 filing.
AEON Biopharma, Inc. reported that Chief Financial Officer John Bencich received a grant of 754,717 shares of Class A common stock in the form of restricted stock units. The award was granted on April 1, 2026 and carries no purchase price per share.
The restricted stock units vest in substantially equal installments on each of the first, second, third and fourth anniversaries of the grant date, contingent on continued service through each vesting date. Following this award, Bencich is shown as directly owning 754,717 shares of Class A common stock.
AEON Biopharma, Inc. filed an initial insider ownership report for its Chief Financial Officer, John Bencich. This filing is a Form 3, which serves as the starting disclosure of his beneficial ownership in AEON as an officer. The report does not list any specific transactions or share movements.